Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 18, 2026Expert Review of Anticancer Therapy

Adjuvant therapy for resectable gastrointestinal stromal tumors: evidence, controversies, and practical guidance

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAnjali ShahGJGeorge JohnAMAnuradha Mehta

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Shah et al. (2026) studied this question.

synapsesocial.com/papers/6aad0bb6de0393d728b8a145https://doi.org/10.1080/14737140.2026.2733840
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Adjuvant treatment of gastrointestinal stromal tumors (GIST)—state of the art, controversies, and future directions2026
  2. 2Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?2024 · 1 citations
  3. 3Clinical outcomes of resected gastrointestinal stromal tumors treated with 3 years of adjuvant imatinib in different genotypes.2026
  4. 4Integrating surgery and targeted therapies in the management of recurrent/metastatic gastrointestinal stromal tumors2025
  5. 5Gastrointestinal stromal tumors (GIST): a contemporary review2026